$LH

Schechter Adam H sold $1.5M of LH

Schechter Adam H (President & CEO) sold 4,669 shares of LABCORP HOLDINGS INC. (LH) at $320.37 ($1.50M total) on 2026-08-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Schechter Adam H
Published Aug 12, 2026, 6:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 6:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LH
Neutral
high confidence
Mentioned
$LH
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LHNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value) and that it was executed under a pre-arranged Rule 10b5-1 plan.

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not provide new operational or financial information.

03

What to watch

The disclosure does not state motives beyond the pre-arranged plan, and the sale size may be routine relative to holdings.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-12, transaction dated 2026-08-11

Background

The article is an SEC Form 4 insider transaction filing for Labcorp Holdings (LH) by its President and CEO, Adam H. Schechter.

Company-level read

Ticker impact

$LHNeutralHigh confidence
Context

SEC Form 4 shows LH CEO Schechter sold 4,669 shares in an open-market transaction on 2026-08-11 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a routine Form 4 with a stated 10b5-1 pre-arranged plan and no accompanying guidance, deal, or regulatory action.

Market effects

No sector-level signal; insider sale does not imply industry-wide change.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can be interpreted as confidence erosion by some traders.

Key entities

  • LH

    Labcorp Holdings Inc., the company whose insider transaction is disclosed.

  • Schechter Adam H

    President and CEO of LH, reporting an open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LHMedAI 9/10

Labcorp’s (NYSE:LH) Q3 2026 sales beat estimates

Labcorp reported Q3 2026 revenue of $3.81B, exceeding estimates by 1.2% and growing 6.9% YoY. Adjusted EPS was $4.78, a 2.9% beat. The company raised full-year revenue and EPS guidance. Operating margin remained steady at 10.6%, while free cash flow margin improved to 10.8%. Organic revenue grew 5.5% YoY.

$LHHighAI 8/10

Labcorp shares edge up on beating estimates, raising guidance

Labcorp Holdings Inc. (NYSE:LH) reported Q3 earnings of $4.78 per share, beating estimates by $0.13, with revenue of $3.81 billion, up 6.9% YoY. The company raised full-year guidance for revenue growth to 5.9%-6.7% and adjusted EPS to $18.30-$18.70. Shares rose 1.46% in pre-market trading. Labcorp also announced four acquisitions and paid $58.2 million in dividends.

$LHHighAI 9/10

Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance

LABCORP HOLDINGS INC. (LH) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Contact: Nickolo Russo - Investors Racquel White - Media Investor@labcorp.com Media@labcorp.com Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance • Results from operations for third quarter 2026 versus third quarter 2025: ◦ Re